To the Editor: New developments in biology and biotechnology 1 and the diversification of the use of marine biological resources in increasingly sophisticated products 2 are accelerating the domestication of marine biodiversity and the emerging patent market of marine biotechnology. Whereas the rate of discovery of new marine species is slow (0.93% per year) 2 , the number of domesticated marine species is growing at about 3% per year 1 , the number of natural marine products of commercial interest (e.g., cosmetics, industrial enzymes or genes derived from marine organisms) and marine gene patents are growing at a rate of 4% per year and 12% per year, respectively 2, 3 , and marine aquaculture production is growing at 7% per year 1 . Collectively, the steep growth in the use of marine biological resources represents a fundamental change in the way humans derive benefits from the oceans 1 .
The sophisticated technology and financial investment required to enter the emerging marine biotechnology market 3, 4 results in dominance by wealthy countries 2, 3 . However, a focus on marine resources involving low-cost technology requirements 5 , such as seaweed, provides an opportunity for developing countries to access this emerging market. Seaweed aquaculture, growing at 7.5% per year 6 , is becoming an important component of marine aquaculture, propelled by a diversification of the demand for seaweed products from traditional uses to bio-energy 7 , cosmetics 8 and biomedicine applications 9 . Hence, seaweed production provides important opportunities for developing countries, and is accordingly growing rapidly in Africa, South America and Southeast Asia 10 .
The combined effect of rapidly increasing domestication and production with increasing demand for seaweed products is likely to promote innovation in seaweed biotechnology. We, therefore, expect patents for processes and applications of marine seaweed farming to grow rapidly. Moreover, we expect that, given the greater access of emerging nations to developments in seaweed biotechnology, the patterns of distribution of these patents among nations should deviate from that of gene patents that require sophisticated technologies and are concentrated in a few developed nations 3 .
Here we examine the growth of seaweed biotechnology, based on the examination of patents for seaweed aquaculture and seaweedderived products registered between 1980 and 2009 (Supplementary Methods). We find that the intellectual property propelling seaweed biotechnology is co-opted by a small number of Asian nations (Japan, China and South Korea hold 84% of all registered seaweed patents) in contrast to the dominance of marine gene patents by Western nations 3 . Nations showed important differencies in the role they play in seaweed patents, production and research rankings, as one country may dominate in one area but not in the others (Fig.1) . Cultivation of seaweed is more widespread than innovation, as seaweed is grown in twice as many nations as those filing patent claims. The vast majority of patents are Rapid growth of seaweed biotechnology provides opportunities for developing nations owned by nations where seaweed production is traditionally important, but that also invest significantly in research (e.g., China and Japan). The remaining patent registrations are distributed among nations that produce little or no seaweed but support a large output of seaweed research (e.g., US and France). In contrast, top-ranking seaweed producers with little invested in research do not participate in the patent market (e.g., The Philippines, Indonesia and Vietnam). Indeed, differences in production and research effort explained 50% of the variability in the number of patents among nations (F = 20.5, P < 0.0001), with research effort emerging as the main driver of differences in the number of patents (accounting for 96% of the variance explained, F = 41.9, P < 0.0001). Among countries that invested substantially in research (those with more than 20 peerreviewed publications on seaweed published in the period 1980-2009), the number of patent registrations increased where seaweed production was higher (e.g., Japan and China), whereas in countries where the research effort was minimal (e.g., Indonesia and Vietnam), the number of patents appeared unrelated to the rate of production. This implies that seaweed aquaculture leads to innovation only when accompanied by substantial scientific effort. Our analysis highlights the importance of research effort in driving innovation and reveals an important return in intellectual property from investments in seaweed biotechnology research.
These results identify an opportunity to reverse the current weak participation of developing countries in the seaweed patent market by strengthening cooperation to transfer technological knowledge and investment to developing nations active in seaweed aquaculture, thereby promoting sustainable development based on their own natural resources, as encouraged by the Convention on Biological Diversity 11 .
In the absence of such cooperative efforts, the emergence of new, more sophisticated biotechnology applications for seaweed products (e.g., cosmetics, bioenergy and biomedicine) may continue to widen the division between developed countries focused on high-value applications and developing countries focused on the mass production of seaweed, where the lack of research investment clearly precludes their participation in the seaweed patent market. 
To the Editor:
In their paper "Performance comparison of benchtop high-throughput sequencing platforms" published in the May 2012 issue, Loman et al. 1 provide a detailed comparison of the metrics associated with three different benchtop DNA sequencing platforms for the assembly of a single genome. Information was given on read-level metrics, such as length, accuracy and alignment, and on assembly-level metrics, such as contig N50 and gap number. The results were discussed in the context of the utility of whole-genome sequencing for public health microbiology. We believe, however, that one of the primary uses for sequencing in clinical microbiology (at least initially) will be in the detection of pathogen transmission
Read and assembly metrics inconsequential for clinical utility of whole-genome sequencing in mapping outbreaks
